Shares of Affirm Holdings, Inc. (NASDAQ:AFRM – Get Free Report) have been assigned an average recommendation of “Reduce” from the eighteen brokerages that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $27.86.
Several analysts have recently commented on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Affirm in a report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Affirm from $24.00 to $35.00 and gave the company a “hold” rating in a report on Friday, February 9th. BMO Capital Markets increased their target price on shares of Affirm from $44.00 to $47.00 and gave the company a “market perform” rating in a report on Monday, February 12th. Barclays lowered their target price on shares of Affirm from $50.00 to $41.00 and set an “overweight” rating for the company in a report on Tuesday, April 16th. Finally, Wedbush restated an “underperform” rating and set a $20.00 price objective on shares of Affirm in a report on Friday, February 9th.
Get Our Latest Analysis on AFRM
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Planned Solutions Inc. purchased a new position in Affirm during the 4th quarter valued at $25,000. Creative Financial Designs Inc. ADV boosted its holdings in shares of Affirm by 82.2% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 665 shares of the company’s stock valued at $33,000 after buying an additional 300 shares in the last quarter. Raleigh Capital Management Inc. bought a new stake in shares of Affirm during the 4th quarter valued at $33,000. Global Wealth Strategies & Associates boosted its holdings in shares of Affirm by 94.0% during the 1st quarter. Global Wealth Strategies & Associates now owns 970 shares of the company’s stock valued at $36,000 after buying an additional 470 shares in the last quarter. Finally, Principal Securities Inc. bought a new stake in shares of Affirm during the 4th quarter valued at $49,000. 69.29% of the stock is owned by hedge funds and other institutional investors.
Affirm Stock Down 4.6 %
Shares of NASDAQ AFRM opened at $31.88 on Friday. The firm has a market cap of $9.78 billion, a PE ratio of -12.80 and a beta of 3.58. Affirm has a 12-month low of $8.80 and a 12-month high of $52.48. The company’s fifty day simple moving average is $35.14 and its 200 day simple moving average is $35.32. The company has a quick ratio of 11.49, a current ratio of 11.49 and a debt-to-equity ratio of 2.35.
Affirm (NASDAQ:AFRM – Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.08. Affirm had a negative net margin of 39.19% and a negative return on equity of 25.10%. The firm had revenue of $591.11 million for the quarter, compared to analyst estimates of $523.92 million. As a group, sell-side analysts forecast that Affirm will post -2.45 earnings per share for the current fiscal year.
Affirm Company Profile
Affirm Holdings, Inc operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time with terms ranging up to 60 months.
Read More
- Five stocks we like better than Affirm
- The Role Economic Reports Play in a Successful Investment Strategy
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Using the MarketBeat Dividend Yield Calculator
- Hilton Demonstrates Asset Light is Right for Investors
- What Are Dividends? Buy the Best Dividend Stocks
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Affirm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirm and related companies with MarketBeat.com's FREE daily email newsletter.